ADVFN Logo
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

FHTX Foghorn Therapeutics Inc

6.44
0.16 (2.55%)
Last Updated: 10:29:56
Delayed by 15 minutes

Period:

Draw Mode:

Volume 2,003
Bid Price 6.40
Ask Price 6.57
News -
Day High 6.5654

Low
2.70

52 Week Range

High
9.97

Day Low 6.26
Company Name Stock Ticker Symbol Market Type
Foghorn Therapeutics Inc FHTX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.16 2.55% 6.44 10:29:56
Open Price Low Price High Price Close Price Prev Close
6.26 6.26 6.5654 6.28
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
76 2,003 $ 6.37 $ 12,752 - 2.70 - 9.97
Last Trade Time Type Quantity Stock Price Currency
10:48:42 1 $ 6.57 USD

Foghorn Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
274.12M 42.57M - 19.23M -108.88M -2.56 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Foghorn Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No FHTX Message Board. Create One! See More Posts on FHTX Message Board See More Message Board Posts

Historical FHTX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week6.567.0355.856.2471,557-0.12-1.83%
1 Month8.038.445.78176.6199,763-1.59-19.80%
3 Months6.038.442.705.30173,4220.416.80%
6 Months6.038.442.704.94137,1030.416.80%
1 Year4.849.972.705.80109,0901.6033.06%
3 Years13.2524.342.7012.08143,576-6.81-51.40%
5 Years18.1228.2652.7012.85143,017-11.68-64.46%

Foghorn Therapeutics Description

Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.

Your Recent History

Delayed Upgrade Clock